Company intelligence / Profile preview
Nanite Therapeutics
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Nanite has generated preclinical proof-of-concept data in animals showing durable, redosable in vivo expression of DNA-encoded biologics (including the anti‑HIV antibody PGT121) using programmable polymer nanoparticles, and is advancing preclinical delivery programs for cystic fibrosis lung gene therapy and other genetic diseases.
- Therapeutic areas
- PulmonologyRare DiseasesInfectious Diseases
- Modalities
- Polymer-drug conjugate therapyNanoparticleGene therapyRNA therapyDNA vaccinemRNA-based drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cystic Fibrosis FoundationBill & Melinda Gates FoundationCMT Research Foundation
Beyond the preview
Go deeper on Nanite Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanite Therapeutics.